Short Interest in ABIVAX Société Anonyme (NASDAQ:ABVX) Expands By 71.2%

ABIVAX Société Anonyme (NASDAQ:ABVX) was the recipient of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 484,900 shares, an increase of 71.2% from the November 15th total of 283,200 shares. Based on an average daily volume of 117,700 shares, the short-interest ratio is presently 4.1 days. Approximately 0.9% of the company’s shares are sold short.

ABIVAX Société Anonyme Stock Down 3.7 %

ABVX stock opened at $7.65 on Friday. The business has a 50 day moving average of $9.52 and a 200 day moving average of $11.39. ABIVAX Société Anonyme has a twelve month low of $7.65 and a twelve month high of $17.02.

Analysts Set New Price Targets

Several brokerages recently issued reports on ABVX. JMP Securities assumed coverage on shares of ABIVAX Société Anonyme in a research report on Wednesday, December 4th. They set an “outperform” rating and a $33.00 price target on the stock. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $38.67.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Several institutional investors and hedge funds have recently modified their holdings of the stock. abrdn plc grew its position in ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after purchasing an additional 198,225 shares during the last quarter. Point72 Asset Management L.P. grew its holdings in shares of ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after buying an additional 119,300 shares during the last quarter. Walleye Capital LLC increased its position in shares of ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock valued at $2,965,000 after acquiring an additional 80,807 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after acquiring an additional 5,900 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.